Skip to main content
Premium Trial:

Request an Annual Quote

LabBook, Nerac Partner to Deliver More Information to Researchers

NEW YORK, Sept 28 – Bioinformatics company LabBook said Thursday it had formed a strategic partnership with Nerac to provide researchers with access to more than 21,000 journals, patents, and specialized scientific databases.

LabBook has developed search engines and software, including an XML browser that queries, manages, and visualizes heterogeneous genomic data, while Nerac maintains a wide-range of research resources for a number of different industries.

“By forming this strategic partnership both Nerac and LabBook will expand their reach into the life science and drug discovery community," Kevin Bouley, president of Nerac, said in a statement. " LabBook's enabling tools and multiple search engines, coupled with our databases, will enhance the certainty of discovery."

Terms of the deal were not disclosed.

LabBook is based in McLean, Va., and Columbus, Ohio. Nerac is based in Tolland, Conn.


The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.